<DOC>
	<DOCNO>NCT01756430</DOCNO>
	<brief_summary>The aim present study evaluate efficacy safety Carvedilol SR versus Carvedilol IR Patients With Essential Hypertension</brief_summary>
	<brief_title>Efficacy Safety Carvedilol SR Versus Carvedilol IR Patients With Essential Hypertension</brief_title>
	<detailed_description>- In patient Essential hypertension evaluate efficacy safety Carvedilol SR ( 32mg , 64mg ) Carvedilol IR ( 25mg QD , 25mg BID ) 8 week . - This study consist placebo run-in period ( 2~4 weeks_single blind ) treatment period ( 8 weeks_double blind ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>age 18 year old screen visit ( visit 1 ) antihypertensive drug take : 90mmHg ≤ mean sitDBP ≤ 109mmHg mean sitSBP &lt; 180mmHg antihypertensive drug take : mean sitDBP ≤ 104mmHg mean sitSBP &lt; 180mmHg randomization visit ( visit 2 ) : 90mmHg ≤ mean sitDBP ≤ 109mmHg mean sitSBP &lt; 180mmHg willing able provide write informed consent 1 . At Screening , difference measure blood pressure select arm ( sitDBP ≥ 10mmHg sitSBP ≥ 20mmHg ) 2. know suspected secondary hypertension ( ex . aortic coarctation , Primary hyperaldosteronism , renal artery stenosis , pheochromocytoma ) 3 . Type I Diabetes Mellitus , Type II Diabetes Mellitus poor glucose control define fast glucosylated hemoglobin ( HbA1c &gt; 9 % ) 4 . Corresponding follow severe heart disease ( Heart failure NYHA functional class 3 , 4 ) ischaemic heart disease within 6 month ( unstable angina myocardial infarction ) myocardiopathy Cor pulmonale aortic stenosis , aortic valvular stenosis , mitral stenosis abnormality conduction system 2nd degree AV block , Complete AV block , Sick Sinus Syndrome , Sinus Block ( In particular , pulse &lt; 50beats / min ) heart attack complication . 5. cerebrovascular disease cerebral infarction , cerebral hemorrhage within 6 month 6. edema glottitis , allergic rhinitis , Respiratory diseases Asthma , Chronic Obstructive Pulmonary Disease . 7 . Peripheral circulatory disturbance ( ex . Raynaud syndrome , intermittent claudication ) 8 . Fluid retention overload require intravenous inotropes . 9. know severe malignant retinopathy ( retinal hemorrhage , visual disturbance , Retinal microaneurysms within 6 month ) 10. define follow laboratory parameter : hepatic dysfunction ( AST/ALT ≥ UNL X 3 ) renal dysfunction ( serum creatinine ≥ UNL X 2 ) 11. surgical medical condition might significantly alter absorption , distribution , metabolism , excretion investigational product ( ex . gastrointestinal tract surgery gastrectomy , gastroenterostomy bypass , active inflammatory bowel syndrome within 12 month prior screen , gastric ulcer need treatment , gastrointestinal/rectal bleeding , impaired pancreatic function pancreatitis , obstruction urinary tract difficulty void ) 12. history drug alcohol dependency within 6 month 13. premenopausal woman ( last menstruation &lt; 12 month ) use adequate contraception , pregnant breastfeed 14. chronic inflammatory status need treatment 15. know hypersensitivity relate carvedilol 16. history malignancy include leukemia lymphoma within past 5 year 17. administration study drug within 28 day prior first IP administration 18. investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Carvedilol SR</keyword>
	<keyword>Carvedilol IR</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Essential Hypertension</keyword>
</DOC>